Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Leerink Partners

November 4, 2024 6:20 AM EST

Leerink Partners analyst David Risinger raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $55.00 (from $53.00) while maintaining a Market Perform rating.

The analyst comments "Bottom line. We are increasing our PT from $53 (7.5x old 25E EPS of $7.06) to $55 (7.5x new 25E... More